Efavirenz and Posaconazole Interaction

Drug interaction information between Efavirenz and Posaconazole.

Efavirenz and Posaconazole have a documented moderate interaction in FDA labeling.

FDA drug labeling documents a moderate-severity interaction between Efavirenz and Posaconazole. This page displays the available source-record category and label text. The category is not an individual risk estimate or medication-combination direction.

Drug A

Efavirenz

NNRTI / NRTI Combination

Drug B

Posaconazole

Azole Antifungal

How They Interact

Efavirenz causes the body to break down posaconazole more quickly, which lowers the amount of medicine available to fight infections.

FDA Label Information

Posaconazole ↓ posaconazole* Avoid concomitant use unless the benefit outweighs the risks.

Frequently Asked Questions

What SPL severity band is on file for Efavirenz/Emtricitabine/Tenofovir + Posaconazole?

Compiled FDA labeling labels this pair moderate. That is a source-record field, not an individual medication-combination decision.

Which drug in this pair has the larger labeled-interaction portfolio?

Efavirenz has 32 labeled pairs on file vs Posaconazole's 27. In the moderate band specifically: Efavirenz has 3 (also Clarithromycin, Sofosbuvir/Velpatasvir); Posaconazole has 5 (also Lovastatin, Suvorexant, Tacrolimus Topical, Vorapaxar).

What mechanism field is on file for Efavirenz/Emtricitabine/Tenofovir and Posaconazole?

Efavirenz causes the body to break down posaconazole more quickly, which lowers the amount of medicine available to fight infections.

Posaconazole carries more major-labeled pairs than Efavirenz

SPL source-record counts only. This page's band is moderate · classes on file: Efavirenz (NNRTI / NRTI Combination); Posaconazole (Azole Antifungal).

Posaconazole has 5 major-labeled pairs vs Efavirenz's 0. This page itself is in the moderate band, not the major band.

Efavirenz

0 major · 3 moderate · 29 minor · 32 total

Posaconazole

5 major · 5 moderate · 17 minor · 27 total

Sources: FDA Drug Labels (SPL) via openFDA (2026). This is for informational purposes only and is not medical advice. This registry does not provide individual medication-combination directions.